Although additional well design ed , worldwide , placebo-controlled and r and omized studies are necessary to confirm the long-term outcomes of naftopidil pharmacotherapy , current data suggest that naftopidil administration in BPH patients provides comparable improvements in total IPSS , QoL , and urinary symptoms from baseline relative to 0.2 mg/d tamsulosin and 8 mg/d silodosin .
However , improvements in Qmax are generally less with naftopidil than with tamsulosin .
Reported adverse effects related to naftopidil administration are negligible and usually mild .
OBJECTIVES The aim of the study was to systematic ally review the effects of the adrenoreceptor A1D antagonist naftopidil in the management of  lower urinary tract symptoms ( LUTS ) .
Intraoperative floppy iris syndrome associated with tamsulosin
Purpose : To assess the incidence and possible causative factors of a newly recognized syndrome , the intraoperative floppy iris ( IFIS )  . Setting : Clinical practice s in Los Altos and San Rafael , California , USA . Methods : A retrospective chart review of consecutive cataract surgeries performed in a 2‐surgeon practice over a 12‐month period ( 706 eyes ; 511 patients ) was used to assess the percentage of cataract patients on systemic sympathetic α‐1 antagonist medications  as well as the percentage of patients who manifested the IFIS . A separate prospect i ve study of 900 consecutive cases ( 741 patients ) performed by another surgeon was used to determine the incidence of IFIS  and the percentage of these patients who were taking α‐1 antagonist medications . Results : Three percent ( 16/511 ) of the patients in the retrospective study , representing 3.0 % ( 25/706 ) of the total eyes , were taking tamsulosin ( Flomax ) for benign prostatic hypertrophy . The overall prevalence of IFIS was 2.0 % ( 10/511 patients ) . The syndrome was noted intraoperatively in 63.0 % ( 10/16 ) of the tamsulosin patients but in none of the 11 patients on other systemic α‐1 blockers . In the prospect i ve study of 900 consecutive cataract surgeries , the prevalence of IFIS was 2.2 % ( 16/741 patients ) . Ninety‐four percent ( 15/16 ) of the IFIS patients were taking or had taken systemic tamsulosin . Twenty‐six patients ( 36 eyes ) in the 2 studies had IFIS associated with systemic tamsulosin . Sphincterotomies and mechanical pupil stretching were ineffective in maintaining adequate pupil dilation in this surgical population . Conclusion : Intraoperative floppy iris syndrome occurred in approximately 2 % of a cataract surgery population and appeared to be caused by tamsulosin , a systemic sympathetic α‐1A antagonist medication that is the most frequently prescribed medication for benign prostatic hypertrophy
Although additional well design ed , worldwide , placebo-controlled and r and omized studies are necessary to confirm the long-term outcomes of naftopidil pharmacotherapy , current data suggest that naftopidil administration in BPH patients provides comparable improvements in total IPSS , QoL , and urinary symptoms from baseline relative to 0.2 mg/d tamsulosin and 8 mg/d silodosin .
However , improvements in Qmax are generally less with naftopidil than with tamsulosin .
Reported adverse effects related to naftopidil administration are negligible and usually mild .
OBJECTIVES The aim of the study was to systematic ally review the effects of the adrenoreceptor A1D antagonist naftopidil in the management of  lower urinary tract symptoms ( LUTS ) .